医学
心力衰竭
蒽环类
心脏毒性
心脏移植
目的地治疗
心脏病学
心室辅助装置
内科学
桥(图论)
移植的桥梁
外科
化疗
癌症
乳腺癌
作者
Jon M. Appel,Kåre Sander,Peter B. Hansen,Jacob Eifer Møller,Anders Krarup‐Hansen,Finn Gustafsson
出处
期刊:Congestive Heart Failure
[Wiley]
日期:2012-04-22
卷期号:18 (5): 291-294
被引量:16
标识
DOI:10.1111/j.1751-7133.2012.00291.x
摘要
©2012 Wiley Periodicals, Inc. Anthracycline treatments are hampered by dose‐related cardiotoxicity, frequently leading to heart failure (HF) with a very poor prognosis. The authors report a case of a 19‐year‐old man developing HF after anthracycline treatment for Ewing sarcoma. Despite medical treatment, his condition deteriorated to terminal HF, leading to implantation of a mechanical left ventricular assist device (LVAD). His heart function recovered, allowing explantation of the device 14 months after implantation. Heart transplantation is often contraindicated in the first years after treatment for cancers, and LVAD as “bridge to recovery” may be warranted in similar patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI